Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: A systematic literature review

Clinical and Experimental Rheumatology

Volumn 33, Issue 4, 2015, Pages 559-569

  López González, Ruth ^a   León, Leticia ^b,c   Loza, Estíbaliz ^d   Redondo, Marta ^c   García de Yébenes, María Jesús ^d   Carmona, Loreto ^d  

^a Hospital Provincial de Zamora   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^d Instituto de Salud Musculoesquelética InMusc Calle Hilarión Eslava   (Spain)

Author keywords

Adherence; Biologic therapy; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

AGE; BIOLOGICAL THERAPY; COMORBIDITY; DISEASE ACTIVITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOGLOBULIN G; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939542883     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. LI P, BLUM MA, Von FELDT J, HENNESSY S, DOSHI JA: Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 2010; 13: 805-12.
2. MARKENSON JA, GIBOFSKY A, PALMER WR et al.: Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
3. BLUM MA, KOO D, DOSHI JA: Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011; 33: 901-13.
4. CURKENDALL S, PATEL V, GLEESON M, CAMPBELL RS, ZAGARI M, DUBOIS R: Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?. Arthritis Rheum 2008; 59: 1519-26.
5. HARLEY CR, FRYTAK JR, TANDON N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9 (6 Suppl.): S136-43.
6. BORAH BJ, HUANG X, ZAROTSKY V, GLOBE D: Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009; 25: 1365-77.
7. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
8. BRAUN J, Van den BERG R, BARALIAKOS X et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
9. GOSSEC L, SMOLEN JS, GAUJOUX-VIALA C et al.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
10. de ACHAVAL S, SUAREZ-ALMAZOR ME: Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol 2010; 5: 313-26.
11. CRAMER JA, ROY A, BURRELL A et al.: Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7.
12. WELLS G, SHEA B, O'CONNELL D et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Vol. 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp: Ottawa Hospital Research Institute (OHRI).
13. OCEBM Levels of Evidence Working Group: The Oxford Levels of Evidence 2. In: Medicine OCfE-B, ed, Vol. 2014; 2011.
14. BROCQ O, ROUX CH, ALBERT C et al.: TNF-alpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74: 148-54.
15. CARMONA L, GOMEZ-REINO JJ: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
16. DUCLOS M, GOSSEC L, RUYSSEN-WITRAND A et al.: Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006; 33: 2433-8.
17. DUCOURAU E, MULLEMAN D, PAINTAUD G et al.: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: R105.
18. FERNANDEZ-NEBRO A, IRIGOYEN MV, URENA I et al.: Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007; 34: 2334-42.
19. GLINTBORG B, OSTERGAARD M, DREYER L et al.: Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
20. GLINTBORG B, OSTERGAARD M, KROGH NS, DREYER L, KRISTENSEN HL, HETLAND ML: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8.
21. GOEKOOP-RUITERMAN YP, de VRIES-BOUWSTRA JK, ALLAART CF et al.: Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 2007; 66: 1227-32.
22. GOMEZ-REINO JJ, CARMONA L: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: R29.
23. GRIJALVA CG, CHUNG CP, ARBOGAST PG, STEIN CM, MITCHEL EF, Jr., GRIFFIN MR: Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45 (Suppl. 2): S66-76.
24. HEIBERG MS, KOLDINGSNES W, MIKKELSEN K et al.: The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 234-40.
25. HETLAND ML, CHRISTENSEN IJ, TARP U et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
26. KRISTENSEN LE, GULFE A, SAXNE T, GEBOREK P: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67: 364-9.
27. KRISTENSEN LE, KARLSSON JA, ENGLUND M, PETERSSON IF, SAXNE T, GEBOREK P: Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010; 62: 1362-9.
28. KRISTENSEN LE, SAXNE T, NILSSON JA, GEBOREK P: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.
29. LEFFERS HC, OSTERGAARD M, GLINTBORG B et al.: Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70: 1216-22.
30. PAVELKA K, FOREJTOVA S, STOLFA J et al.: Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009; 27: 958-63.
31. PUNZI L, MATUCCI-CERINIC M, CANTINI F et al.: Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo 2011; 63: 18-28.
32. YAMANAKA H, TANAKA Y, INOUE E et al.: Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011; 21: 122-33.
33. ZINK A, LISTING J, KARY S et al.: Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274-9.
34. AGARWAL SK, MAIER AL, CHIBNIK LB et al.: Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005; 53: 872-8.
35. ARENDS S, BROUWER E, Van der VEER E et al.: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
36. ATZENI F, ANTIVALLE M, PALLAVICINI FB et al.: Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 431-7.
37. BARTELDS GM, KRIECKAERT CL, NURMOHAMED MT et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
38. BERTHELOT JM, BENOIST-GERARD S, le GOFF B, MULLER-CHEVALET F, MAUGARS Y: Outcome and safety of TNFalpha antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials. Joint Bone Spine 2010; 77: 564-9.
39. COATES LC, CAWKWELL LS, NG NW et al.: Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 897-900.
40. CONDE GARCIA MC, FERNANDEZ FEIJOO MA, CALLEJA HERNANDEZ MA: [Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital]. Farm Hosp 2009; 33: 305-11.
41. DELABAYE I, De KEYSER F: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther 2010; 12: R121.
42. den BROEDER AA, de JONG E, FRANSSEN MJ, JEURISSEN ME, FLENDRIE M, Van den HOOGEN FH: Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-2.
43. DOUGADOS M, WELLS G, SCHMIDELY N et al.: Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. Clin Exp Rheumatol 2010; 28: 258-60.
44. DU PAN SM, DEHLER S, CIUREA A, ZISWILER HR, GABAY C, FINCKH A: Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
45. FIGUEIREDO IT, MOREL J, SANY J, COMBE B: Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 18-23.
46. FLEISCHMANN R, BAUMGARTNER SW, WEISMAN MH, LIU T, WHITE B, PELOSO P: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-84.
47. FLENDRIE M, CREEMERS MC, WELSING PM, den BROEDER AA, Van RIEL PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 2): ii30-3.
48. GRIJALVA CG, KALTENBACH L, ARBOGAST PG, MITCHEL EF, Jr., GRIFFIN MR: Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res (Hoboken) 2010; 62: 730-4.
49. HELDMANN F, BRANDT J, Van der HORST-BRUINSMA IE et al.: The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
50. HYRICH KL, LUNT M, WATSON KD, SYMMONS DP, SILMAN AJ: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
51. HYRICH KL, WATSON KD, SILMAN AJ, SYMMONS DP: Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
52. KARLSSON JA, KRISTENSEN LE, KAPETA-NOVIC MC, GULFE A, SAXNE T, GEBOREK P: Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 507-13.
53. KLARESKOG L, GAUBITZ M, RODRIGUEZ-VALVERDE V, MALAISE M, DOUGADOS M, WAJDULA J: Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 238-47.
54. KONTTINEN L, TUOMPO R, UUSITALO T et al.: Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 2007; 26: 1693-700.
55. LEVALAMPI T, KORPELA M, VUOLTEENAHO K, MOILANEN E: Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival. Rheumatol Int 2010; 30: 1611-20.
56. LORD PA, FARRAGHER TM, LUNT M, WATSON KD, SYMMONS DP, HYRICH KL: Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
57. MARCHESONI A, ZACCARA E, GORLA R et al.: TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
58. MATTEY DL, BROWNFIELD A, DAWES PT: Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1180-7.
59. MEASE PJ, COHEN S, GAYLIS NB et al.: Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010; 37: 917-27.
60. MORELAND LW, WEINBLATT ME, KEYSTONE EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006; 33: 854-61.
61. OEI HB, HOOKER RS, CIPHER DJ, REIMOLD A: High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 926-34.
62. OGALE S, HITRAYA E, HENK HJ: Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
63. SAAD AA, ASHCROFT DM, WATSON KD, HYRICH KL, NOYCE PR, SYMMONS DP: Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
64. SAAD AA, ASHCROFT DM, WATSON KD, SYMMONS DP, NOYCE PR, HYRICH KL: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 697-705.
65. SODERLIN MK, PETERSSON IF, GEBOREK P: The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012; 41: 1-9.
66. SPADARO A, PUNZI L, MARCHESONI A et al.: Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) 2010; 49: 1107-11.
67. TANAKA Y, TAKEUCHI T, INOUE E et al.: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008; 18: 146-52.
68. Van den BROEK M, KLARENBEEK NB, DIRVEN L et al.: Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the Best study. Ann Rheum Dis 2011; 70: 1389-94.
69. VANDER CRUYSSEN B, DUREZ P, WESTHOVENS R, De KEYSER F: Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther 2010; 12: R77.
70. Vander CRUYSSEN B, Van LOOY S, WYNS B et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006; 8: R112.
71. VENETSANOPOULOU AI, VOULGARI PV, ALAMANOS Y, PAPADOPOULOS CG, MARKATSELI TE, DROSOS AA: Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int 2007; 27: 935-9.
72. YAZICI Y, McCMORRIS BJ, DARKOW T, ROSENBLATT LC: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 907-13.